No Increase in Seizure Incidence With Enzalutamide in mCRPC

Share this content:
No Increase in Seizure Incidence With Enzalutamide in mCRPC
No Increase in Seizure Incidence With Enzalutamide in mCRPC

FRIDAY, Dec. 8, 2017 (HealthDay News) -- For patients with metastatic castration-resistant prostate cancer (mCRPC) with at least one risk factor for seizure at baseline, treatment with enzalutamide is not associated with increased incidence of seizure, according to research published online Dec. 7 in JAMA Oncology.

Susan Slovin, M.D., Ph.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues examined the incidence of seizure among patients receiving enzalutamide for mCRPC. A total of 366 patients receiving treatment with oral enzalutamide (160 mg/day) were evaluated.

The researchers found that medication that lowered seizure threshold, history of brain injury, and history of cerebrovascular accident or transient ischemic attack were risk factors for seizure at baseline (57.2, 26.5, and 22.2 percent, respectively). Within four months of enzalutamide initiation, four patients (1.1 percent) had at least one confirmed seizure; three additional patients (0.8 percent) experienced a seizure within four months following the four-month study period. The incidence of confirmed seizure was 2.6 per 100 patient-years. Overall, 84.4 percent of patients receiving enzalutamide experienced at least one treatment-emergent adverse event.

"Incidence of seizure is similar in patients with mCRPC and similar seizure risk factors with or without enzalutamide exposure," the authors write. "The risk profile presented, along with the previously established efficacy of enzalutamide, suggests that enzalutamide can benefit patients with a history of seizures or other predisposing factors, but each patient should be closely monitored for the duration of treatment."

Several authors disclosed financial ties to pharmaceutical companies, including Astellas Pharma and Medivation, co-developers of enzalutamide.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards $4.62B in Johnson & Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »